Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $30.0852W HIGH $99.73
Volume
195.06 K
Value Traded
200.36 M
Short % Float
9.09%
+7.21%Week
+6.93%1 Month
+11.97%3 Month
+152.91%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
8.00 B
EPS (TTM)
1.35
P/E Ratio
73.33
Ent. Value
7.54 B
Total Shares
80.69 M
Float Shares
53.15 M
Insiders
34.14%
Institutions
67.29%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
HNGE Catalyst Timeline
Dated clinical, regulatory and corporate events for Hinge Health, Inc.
Past FDA Catalysts and PDUFA Decisions
How HNGE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Hinge Health, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every HNGE program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Pursley JamesOfficer (President) | Sell | -9,065 690,844 held | $93.37 | 09/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HNGE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 0.4 % (-42.9 %) | 41.50 M | 500.00 K | -74.09% ( -1.43 M) |
HNGE Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HNGE ranks across every disease it competes in
Competitive Position is a premium feature
See how HNGE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHNGE News
-HNGE
Aug 4, 2026Hinge Health to acquire Cylinder Health, expanding into gastrointestinal care
Hinge Health has announced its acquisition of Cylinder Health for $105 million, aiming to enhance its offerings in gastrointestinal care. This move will complement its existing programs for musculoskeletal and migraine care. The new GI Care Program is expected to address the needs of a significant portion of U.S. adults affected by digestive health issues.
Read more →-HNGE
Aug 4, 2026Hinge Health reports record second quarter 2026 financial results; signs definitive agreement to acquire Cylinder Health
Hinge Health, Inc. reported impressive financial results for the second quarter of 2026, achieving $213 million in revenue, which marks a 53% increase year-over-year. The company also tripled its free cash flow compared to the previous year. Additionally, Hinge Health announced a definitive agreement to acquire Cylinder Health, further expanding its business operations.
Read more →-HNGE
Jul 30, 2026Study finds Hinge Health significantly lowers fall risk for adults aged 65+
Hinge Health, Inc. announced a study demonstrating a significant decrease in fall risk among adults aged 65 and older. The research revealed that participants using Hinge Health experienced 37% fewer falls and a 57% reduction in emergency room visits compared to a control group. This study highlights the effectiveness of Hinge Health's approach in improving safety for older adults.
Read more →-HNGE
Jul 6, 2026Hinge Health to announce second quarter 2026 financial results on August 4, 2026
Hinge Health is scheduled to announce its financial results for the second quarter of 2026 on August 4, 2026. The announcement is expected to provide insights into the company's performance during this period. Details regarding the financial results will likely be shared in a press release or during a conference call.
Read more →-HNGE
Jun 10, 2026Hinge Health adds surgery to HingeSelect, delivering a fully integrated musculoskeletal care platform
Hinge Health has expanded its HingeSelect platform to include surgical options, enhancing its integrated musculoskeletal care offerings. This development aims to provide comprehensive care solutions for patients. The addition signifies Hinge Health's commitment to improving patient outcomes through a more holistic approach to musculoskeletal health.
Read more →-HNGE
Jun 9, 2026Hinge Health hosts its first Investor Day and raises guidance
Hinge Health recently hosted its inaugural Investor Day, where it provided updates on its business performance and future outlook. The company raised its guidance, indicating a positive trajectory in its operations. However, specific details regarding the financial implications were not disclosed in the article.
Read more →-HNGE
Jun 3, 2026Hinge Health proven to deliver 3.0x ROI with the largest study of its kind
Hinge Health has conducted the largest study of its kind, demonstrating a 3.0x return on investment (ROI). The details of the study and its implications for the company's future performance are not provided in the article. The findings may influence stakeholders' perception of Hinge Health's value in the market.
Read more →-HNGE
May 5, 2026Hinge Health reports record first quarter 2026 financial results
Hinge Health has announced its financial results for the first quarter of 2026, reporting record figures. The announcement highlights the company's growth and performance during this period. However, specific financial details and metrics were not provided in the article.
Read more →-HNGE
Apr 29, 2026Hinge Health launches comprehensive Migraine Care Program
Hinge Health has launched a new Migraine Care Program aimed at providing drug-free pain relief and personalized management for migraine sufferers. The program utilizes the FDA-cleared Enso device, which offers rapid pain relief, alongside AI-powered insights for trigger management. With a focus on proactive prevention through exercise therapy, the program is set to roll out in May 2026 and has already gained significant employer interest.
Read more →-HNGE
Feb 10, 2026Hinge Health reports fourth quarter and full year 2025 financial results San Francisco, California
Hinge Health reported impressive financial results for Q4 and full year 2025, achieving record revenue of $587.9 million, a 51% increase from the previous year. The company also saw substantial growth in cash flow, with free cash flow rising by 297%. Despite a noted increase in GAAP losses from operations, Hinge Health's positive future guidance signals confidence in continued growth and operational automation. The announcement reflects strong momentum within the digital musculoskeletal care market.
Read more →-HNGE
Nov 12, 2025Hinge Health announces $250 million share repurchase program San Francisco, California –
Hinge Health, Inc. (NYSE: HNGE) has announced a $250 million share repurchase program approved by its board of directors. The company has shown strong financial performance, generating $108 million in cash from operations in the first three quarters of 2025 and maintaining nearly $500 million in cash and investments. Hinge Health aims to balance share repurchases with continued investment in growth and improving member outcomes, leveraging its AI-powered care model and enhancing operational efficiency.
Read more →-HNGE
Nov 4, 2025▲ +6.2%on this news
Hinge Health reports third quarter 2025 financial results San Francisco, California –
Hinge Health reported strong financial results for Q3 2025, with revenue growth of 53% year-over-year reaching $154.2 million. They surpassed 1.5 million lifetime members and generated record free cash flow of $81.3 million. However, the company experienced an increase in GAAP loss from operations, amounting to $6.1 million. Hinge Health also provided guidance for Q4 2025 and raised their full year revenue expectations, reflecting a positive outlook amidst rising healthcare costs.
Read more →-HNGE
Aug 5, 2025Hinge Health Reports Second Quarter 2025 Financial Results San Francisco, California –
Hinge Health, Inc. (NYSE: HNGE) reported impressive financial results for Q2 2025, showcasing a 55% increase in revenue to $139.1 million. Coupled with a rise in clients by 32% to 2,359, the company's operational performance highlighted its growing acceptance in the market. However, the company recorded a significant GAAP loss driven by stock-based compensation, and its gross margins declined slightly year-over-year. Expectations for the third quarter suggest continued growth, with projected revenues between $141 million and $143 million.
Read more →About Hinge Health, Inc.
Headquarters455 MARKET STREET, SAN FRANCISCO, CA, 94105
BIOPHARMAWATCH ELITE PLUS
Trade the next HNGE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime